NO973122L - Middel for å minske okkular spenning - Google Patents

Middel for å minske okkular spenning

Info

Publication number: NO973122L
Authority: NO; Norway
Prior art keywords: alkyl; phenyl; hydrogen; straight; ocular tension
Prior art date: 1995-11-14

Application number

NO973122A

Other languages

English (en)

Norwegian (no)

Other versions

NO973122D0 (no

Inventor

Hajimu Kurumatani

Ayako Kawashima

Musafumi Isogaya

Hisanori Wakita

Original Assignee

Toray Industries

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-14

Filing date

1997-07-04

Publication date

1997-08-27

1997-07-04 Application filed by Toray Industries filed Critical Toray Industries

1997-07-04 Publication of NO973122D0 publication Critical patent/NO973122D0/no

1997-08-27 Publication of NO973122L publication Critical patent/NO973122L/no

Links

239000003814 drug Substances 0.000 claims abstract description 11
208000010412 Glaucoma Diseases 0.000 claims abstract description 7
206010030043 Ocular hypertension Diseases 0.000 claims abstract description 6
239000004615 ingredient Substances 0.000 claims abstract description 6
150000003839 salts Chemical class 0.000 claims abstract description 6
238000001356 surgical procedure Methods 0.000 claims abstract description 5
229940124597 therapeutic agent Drugs 0.000 claims abstract description 4
125000000217 alkyl group Chemical group 0.000 claims description 49
-1 nitro, cyano, methoxy, phenyl Chemical group 0.000 claims description 29
239000001257 hydrogen Substances 0.000 claims description 28
229910052739 hydrogen Inorganic materials 0.000 claims description 28
150000001875 compounds Chemical class 0.000 claims description 23
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
230000000694 effects Effects 0.000 claims description 19
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 12
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 12
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 12
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 12
229910052794 bromium Inorganic materials 0.000 claims description 12
229910052801 chlorine Inorganic materials 0.000 claims description 12
239000000460 chlorine Substances 0.000 claims description 12
229910052731 fluorine Inorganic materials 0.000 claims description 12
239000011737 fluorine Substances 0.000 claims description 12
201000010099 disease Diseases 0.000 claims description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
150000002431 hydrogen Chemical class 0.000 claims description 9
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
125000001424 substituent group Chemical group 0.000 claims description 8
229940079593 drug Drugs 0.000 claims description 7
101100005986 Caenorhabditis elegans cth-2 gene Proteins 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
125000002947 alkylene group Chemical group 0.000 claims description 4
125000003710 aryl alkyl group Chemical group 0.000 claims description 4
150000001768 cations Chemical class 0.000 claims description 4
238000009472 formulation Methods 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
125000002252 acyl group Chemical group 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
MOOGMTSTAOOGOI-UHFFFAOYSA-N 4-acetamido-2-phenoxybenzamide Chemical compound O(C1=CC=CC=C1)C1=C(C(=O)N)C=CC(=C1)NC(C)=O MOOGMTSTAOOGOI-UHFFFAOYSA-N 0.000 claims description 2
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
125000003435 aroyl group Chemical group 0.000 claims description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
238000000034 method Methods 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
125000004965 chloroalkyl group Chemical group 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 abstract description 12
230000003247 decreasing effect Effects 0.000 abstract 2
KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 8
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 6
101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 5
206010020565 Hyperaemia Diseases 0.000 description 4
239000003889 eye drop Substances 0.000 description 4
150000003180 prostaglandins Chemical class 0.000 description 4
230000000007 visual effect Effects 0.000 description 4
229940125904 compound 1 Drugs 0.000 description 3
125000000753 cycloalkyl group Chemical group 0.000 description 3
229960001123 epoprostenol Drugs 0.000 description 3
229940094443 oxytocics prostaglandins Drugs 0.000 description 3
239000002904 solvent Substances 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000000654 additive Substances 0.000 description 2
210000001742 aqueous humor Anatomy 0.000 description 2
229940012356 eye drops Drugs 0.000 description 2
230000005669 field effect Effects 0.000 description 2
229960002240 iloprost Drugs 0.000 description 2
HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
150000003174 prostaglandin I2 derivatives Chemical class 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
UQOQENZZLBSFKO-KTHIOYPCSA-N (z)-7-[(1s)-5-[(e,3s)-3-hydroxyoct-1-enyl]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid Chemical compound CCCCC[C@H](O)\C=C\C1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-KTHIOYPCSA-N 0.000 description 1
GHSCYMOJHVOGDJ-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-amino-2-hydroxybenzoate Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1O GHSCYMOJHVOGDJ-UHFFFAOYSA-N 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
206010020852 Hypertonia Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010067013 Normal tension glaucoma Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
239000000219 Sympatholytic Substances 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000003182 bronchodilatating effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
201000002978 low tension glaucoma Diseases 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
239000000734 parasympathomimetic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229960001416 pilocarpine Drugs 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
150000003176 prostaglandin J2 derivatives Chemical class 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
229940127230 sympathomimetic drug Drugs 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
229960004605 timolol Drugs 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229950008081 unoprostone isopropyl Drugs 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Eye Examination Apparatus (AREA)
Prostheses (AREA)
Window Of Vehicle (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Laser Surgery Devices (AREA)

NO973122A 1995-11-14 1997-07-04 Middel for å minske okkular spenning NO973122L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP29578995		1995-11-14
PCT/JP1996/003351 WO1997017974A1 (fr)	1995-11-14	1996-11-14	Depresseur oculaire

Publications (2)

Publication Number	Publication Date
NO973122D0 NO973122D0 (no)	1997-07-04
NO973122L true NO973122L (no)	1997-08-27

Family

ID=17825188

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO973122A NO973122L (no)	1995-11-14	1997-07-04	Middel for å minske okkular spenning

Country Status (11)

Country	Link
US (1)	US6127413A (de)
EP (1)	EP0795331B1 (de)
KR (1)	KR19980701417A (de)
CN (1)	CN1127342C (de)
AT (1)	ATE215824T1 (de)
AU (1)	AU717104B2 (de)
CA (1)	CA2210255A1 (de)
DE (1)	DE69620573T2 (de)
ES (1)	ES2171742T3 (de)
NO (1)	NO973122L (de)
WO (1)	WO1997017974A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997041864A1 (fr) *	1996-05-07	1997-11-13	Kaken Pharmaceutical Co., Ltd.	Preparations ophtalmiques
US20090016981A1 (en)	2006-05-03	2009-01-15	Allergan, Inc.	Therapeutic compounds
US7439372B2 (en) *	2006-05-03	2008-10-21	Allergan, Inc.	Therapeutic compounds
RU2509768C2 (ru)	2008-09-10	2014-03-20	Асахи Гласс Компани, Лимитед	Новое производное простагландина i2
PT2545917T (pt) *	2010-03-08	2016-10-25	Kaken Pharma Co Ltd	Novo agonista de ep4

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2476684A1 (fr) *	1980-02-21	1981-08-28	Interox	Procede pour inhiber la corrosion d'appareils en titane
US4775692A (en) *	1986-01-24	1988-10-04	Toray Industries, Inc.	2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives
DE3886936T2 (de) *	1987-10-16	1994-04-28	Toray Industries	2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLEN 2-PGI-DERIVATE, VERFAHREN ZUR HERSTELLUNG UND DEREN VERWENDUNG.
WO1997041864A1 (fr) *	1996-05-07	1997-11-13	Kaken Pharmaceutical Co., Ltd.	Preparations ophtalmiques

1996
- 1996-11-14 CN CN96192471A patent/CN1127342C/zh not_active Expired - Fee Related
- 1996-11-14 CA CA002210255A patent/CA2210255A1/en not_active Abandoned
- 1996-11-14 EP EP96938475A patent/EP0795331B1/de not_active Expired - Lifetime
- 1996-11-14 AT AT96938475T patent/ATE215824T1/de not_active IP Right Cessation
- 1996-11-14 US US08/875,022 patent/US6127413A/en not_active Expired - Fee Related
- 1996-11-14 WO PCT/JP1996/003351 patent/WO1997017974A1/ja active IP Right Grant
- 1996-11-14 DE DE69620573T patent/DE69620573T2/de not_active Expired - Fee Related
- 1996-11-14 ES ES96938475T patent/ES2171742T3/es not_active Expired - Lifetime
- 1996-11-14 KR KR1019970704807A patent/KR19980701417A/ko not_active Application Discontinuation
- 1996-11-14 AU AU75873/96A patent/AU717104B2/en not_active Ceased
1997
- 1997-07-04 NO NO973122A patent/NO973122L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP0795331B1 (de)	2002-04-10
KR19980701417A (ko)	1998-05-15
ATE215824T1 (de)	2002-04-15
DE69620573T2 (de)	2002-08-08
US6127413A (en)	2000-10-03
AU717104B2 (en)	2000-03-16
EP0795331A4 (de)	1999-07-14
AU7587396A (en)	1997-06-05
ES2171742T3 (es)	2002-09-16
CN1127342C (zh)	2003-11-12
EP0795331A1 (de)	1997-09-17
CN1177926A (zh)	1998-04-01
DE69620573D1 (de)	2002-05-16
CA2210255A1 (en)	1997-05-22
NO973122D0 (no)	1997-07-04
WO1997017974A1 (fr)	1997-05-22

Legal Events

Date	Code	Title	Description
2002-07-29	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
CA2180008C (en)	2006-06-13	Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US5688819A (en)	1997-11-18	Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5288754A (en)	1994-02-22	Polar C-1 esters of prostaglandins
US5462968A (en)	1995-10-31	EP2 -receptor agonists as agents for lowering intraocular pressure
US6403649B1 (en)	2002-06-11	Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5698598A (en)	1997-12-16	EP2 -receptor agonists as agents for lowering intraocular pressure
US5741810A (en)	1998-04-21	Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
US6160129A (en)	2000-12-12	Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
NO973122L (no)	1997-08-27	Middel for å minske okkular spenning
US5166175A (en)	1992-11-24	Treatment of ocular hypertension with a synergistic combination
KR19990028646A (ko)	1999-04-15	안과용제
US5262437A (en)	1993-11-16	Homo-prostaglandin derivatives as ocular hypotensives
US5405846A (en)	1995-04-11	Treatment of ocular hypertension with a synergistic combination
US5328933A (en)	1994-07-12	Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
EP0562006B1 (de)	1998-04-08	Okulare hypotensive homo-prostaglandinderivate
US5767154A (en)	1998-06-16	5-trans-prostaglandins of the F series and their use as ocular hypotensives
US5312842A (en)	1994-05-17	Cyclopentane heptenylsulfinylalkyl and heptanylsulfinylalkyl-2-aliphatic or aryl aliphatic derivatives
US6124353A (en)	2000-09-26	Method of treating ocular hypertension with 8-epi prostaglandins
US5194449A (en)	1993-03-16	Use of prostaglandin F3α as an ocular hypotensive agent